BioMarin Pharmaceutical (NASDAQ: BMRN), headquartered in San Rafael, California, is a rare-disease biotech with a commercial portfolio spanning peptide therapeutics, enzyme replacement, gene therapy, and small-molecule chaperone approaches. The company's flagship peptide franchise is Voxzogo (vosoritide), a C-type natriuretic peptide (CNP) analog administered as a daily subcutaneous injection for the treatment of achondroplasia in pediatric patients.
Voxzogo delivered Q2 2026 revenue of $253 million (+14% year-over-year) despite the recent US launch of a competitive weekly dosing option (BridgeBio's infigratinib for children with achondroplasia); approximately 90% of US pediatric patients on Voxzogo therapy remained on treatment through July. BioMarin management now expects Voxzogo to reach at least $1 billion in annual sales, making it the first BioMarin product to achieve blockbuster status.
On Monday August 31, 2026, BioMarin and Ascendis Pharma announced a binding global settlement and license term sheet resolving all litigation and disputes related to Ascendis's YUVIWEL (navepegritide, TransCon CNP for achondroplasia and hypochondroplasia). BioMarin retains 20% royalties on YUVIWEL U.S. net sales and 18% royalties on European Union, South Korea, and Brazil net sales through May 20, 2030, and dismisses the pending U.S. ITC Section 337 investigation plus litigation in Brazil, Denmark, Germany, South Korea, and the U.S. Northern District of California. BioMarin's Voxzogo franchise continues uninterrupted alongside the royalty stream from the competing YUVIWEL product.
The rare-disease portfolio expanded meaningfully through the Amicus Therapeutics acquisition, which added GALAFOLD (migalastat oral chaperone for Fabry disease) and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat for late-onset Pompe disease). BioMarin expects $220 million in non-GAAP cost synergies fully realized by 2028 and substantial non-GAAP diluted EPS accretion beginning 2027. The Palynziq (pegvaliase-pqpz) franchise for phenylketonuria continues to grow. ROCTAVIAN (valoctocogene roxaparvovec, hemophilia A AAV gene therapy) was voluntarily withdrawn from the market in Q1 2026. Total Q2 2026 revenue reached $990 million (+20% YoY) with non-GAAP diluted EPS of $0.54 beating the $0.23 consensus. Stories here cover BioMarin trial readouts, franchise commercial performance, and Amicus integration progress. See [[voxzogo]], [[vosoritide]], and [[achondroplasia]] for adjacent threads.
Ascendis Pharma (NASDAQ: ASND) and BioMarin Pharmaceutical (NASDAQ: BMRN) announced Monday August 31, 2026 a binding term sheet for a global settlement and license agreement resolving all litigation and disputes related to YUVIWEL (navepegritide, TransCon C-type natriuretic peptide for achondroplasia and hypochondroplasia). Terms: BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction, and waives certain regulatory rights and exclusivities. Ascendis makes royalty payments to BioMarin of 20% on U.S. net sales and 18% on European Union, South Korea, and Brazil net sales from first commercial sale through May 20, 2030. BioMarin dismisses the pending U.S. International Trade Commission Section 337 investigation plus litigation in Brazil, Denmark, Germany, South Korea, and the U.S. Northern District of California. The settlement covers all current and potential YUVIWEL indications, including achondroplasia and hypochondroplasia, and removes the largest overhang on the Ascendis TransCon peptide platform.
Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.
BridgeBio Pharma (NASDAQ: BBIO) priced a 5,000,000-share secondary offering of common stock on Friday August 14, 2026 on behalf of selling stockholder KKR Genetic Disorder L.P. at the August 13 closing price of $81.21 per share on Nasdaq. The implied secondary-market proceeds to KKR total roughly $406 million. BridgeBio is not selling any shares and will not receive any of the proceeds; the transaction diversifies BridgeBio's institutional shareholder base as KKR reduces its position following a multi-year holding period. The offering is expected to close August 17, 2026 with William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as joint book-running managers. The BridgeBio commercial franchise includes infigratinib, the weekly-dosing FGFR inhibitor for achondroplasia that competes directly against BioMarin's Voxzogo (vosoritide, daily subcutaneous C-type natriuretic peptide analog) and Ascendis's newly-launched YUVIWEL (weekly TransCon C-type natriuretic peptide). The three-way competitive dynamic in pediatric achondroplasia now involves daily-injectable (Voxzogo), weekly-injectable peptide (YUVIWEL), and weekly-oral small-molecule (infigratinib) options, and the BridgeBio franchise is positioned at the small-molecule end of that spectrum. Although infigratinib is not itself a peptide analog, the achondroplasia commercial category is one of the fastest-growing peptide-adjacent pediatric-rare-disease indications following the July 8, 2026 New England Journal of Medicine publication of the Ascendis TRANSCEND trial results and the June 2026 YUVIWEL FDA approval.
Ascendis Pharma (NASDAQ: ASND) shares fell approximately 2.4% premarket Friday August 14, 2026 to $249.28 (compared to Thursday close of $255.46) despite reporting Q2 2026 EPS of $2.83 (beating the $1.51 analyst consensus by 87%) on revenue of $339.3 million (beating the $326.5 million consensus). Q2 2026 product revenue reached €315 million (+105% year-over-year) led by YORVIPATH (palopegteriparatide) at €252 million, SKYTROFA (lonapegsomatropin) at €55 million, and YUVIWEL (TransCon CNP for achondroplasia) at €8 million in its first US quarter with 220+ patient enrollments through July 31. The company ended Q2 2026 with €812 million in cash, no bank or convertible debt, and expects to generate more than €500 million in operating cash flow this year. The market response reflects investors balancing the substantive beat against the ongoing International Trade Commission (ITC) patent-infringement case brought by BioMarin Pharmaceutical (NASDAQ: BMRN) over the YUVIWEL launch. BioMarin owns U.S. Patent No. RE48,267 covering peptide analog variants including its FDA-approved Voxzogo (vosoritide). A first ITC opinion is expected in August 2026 following the March 26, 2026 Federal Circuit ruling in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. that a party cannot use voluntary dismissal to restart a statutory deadline it already missed. The case represents the first substantive peptide-vs-peptide patent battle in the achondroplasia commercial category.
Ascendis Pharma (NASDAQ: ASND) reported Thursday August 13, 2026 Q2 2026 financial results with product revenue of €315 million (+105% year-over-year). YORVIPATH (palopegteriparatide, a TransCon parathyroid hormone peptide analog for chronic hypoparathyroidism) delivered €252 million on consistent new patient demand in the US and continued ex-US global launch expansion with full reimbursement in additional markets. SKYTROFA (lonapegsomatropin, a TransCon growth hormone peptide for pediatric growth hormone deficiency) delivered €55 million. YUVIWEL (TransCon C-type natriuretic peptide for achondroplasia) delivered €8 million with more than 220 US patient enrollments through July 31, 2026. Total Q2 revenue reached €339 million (+100% YoY) including €24 million in collaboration and milestone income. The YUVIWEL launch positions Ascendis directly against BioMarin's Voxzogo (vosoritide) in the same achondroplasia pediatric indication, opening a new front in the CNP peptide analog commercial category. YORVIPATH's €252 million quarterly revenue trajectory suggests a $1+ billion annual run-rate for the peptide franchise by end of 2026, a notable rare-disease peptide launch magnitude. Ascendis's TransCon platform uses a transient linker chemistry to release parent drug over an extended half-life, allowing weekly dosing of peptides that natively have short in vivo lifespans.
BioMarin Pharmaceutical (NASDAQ: BMRN) Q2 2026 earnings detail: VOXZOGO (vosoritide, C-type natriuretic peptide analog administered as a daily subcutaneous injection for achondroplasia in pediatric patients) delivered $253 million in revenue (+14% year-over-year) despite the recent US launch of a competitive weekly dosing option (BridgeBio's infigratinib for children with achondroplasia). Approximately 90% of US pediatric patients on VOXZOGO therapy remained on treatment through July, addressing prior investor concerns about competitive pressure. Management now expects VOXZOGO to reach at least $1 billion in annual sales, making it BioMarin's first product to achieve the blockbuster threshold. Broader Q2 2026 revenue of $990 million (+20% YoY) beat consensus by a wide margin; non-GAAP diluted EPS of $0.54 beat $0.23 consensus. The Amicus Therapeutics acquisition integration adds GALAFOLD (migalastat for Fabry disease) and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat oral chaperone for late-onset Pompe disease) to the BioMarin rare-disease portfolio, with $220 million in non-GAAP cost synergies expected to be fully realized by 2028. The Amicus deal also positions BioMarin to accelerate non-GAAP diluted EPS accretion beginning 2027 with the integrated commercial and manufacturing infrastructure absorbing GALAFOLD and Pompe franchises. BioMarin raised full-year 2026 guidance on both revenue and non-GAAP diluted EPS.
BioMarin Pharmaceutical (NASDAQ: BMRN) reported Q2 2026 financial results after market close Thursday August 6, 2026 with total revenue of $990 million (+20% year-over-year), approaching the $1 billion quarterly threshold. Non-GAAP diluted EPS of $0.54 beat the $0.23 analyst consensus. Growth drivers: continued commercial strength of Voxzogo (vosoritide, C-type natriuretic peptide analog administered as a daily subcutaneous injection for achondroplasia in pediatric patients); contribution from the completed Amicus Therapeutics acquisition adding GALAFOLD (migalastat for Fabry disease) and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat oral chaperone for late-onset Pompe disease) to the BioMarin rare-disease portfolio; and continued growth of Palynziq (pegvaliase-pqpz for phenylketonuria). ROCTAVIAN (valoctocogene roxaparvovec, hemophilia A AAV gene therapy) revenue continued to decline following the Q1 2026 voluntary market withdrawal announced earlier in the year. The Amicus acquisition adds cost synergies expected to accelerate revenue growth, non-GAAP diluted EPS accretion, non-GAAP operating margin expansion, and operating cash flow through the mid-2030s per BioMarin management commentary. BioMarin's Voxzogo peptide franchise represents one of the sole approved peptide therapies in the pediatric endocrine indication space and continues to demonstrate the commercial scalability of the C-type natriuretic peptide modality.
BioMarin Pharmaceutical (NASDAQ: BMRN) hosts its Q2 2026 financial results conference call and webcast Thursday August 6, 2026 at 4:30 PM ET. Analyst focus areas: Voxzogo (vosoritide) commercial trajectory in achondroplasia (Voxzogo is a C-type natriuretic peptide analog administered by daily subcutaneous injection, making it a substantive peptide franchise for the site's coverage); ROCTAVIAN (valoctocogene roxaparvovec) hemophilia A AAV gene therapy commercial ramp and payer coverage; Palynziq (pegvaliase-pqpz) for phenylketonuria (PKU) revenue trajectory; and the broader rare-disease enzyme replacement franchise including VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), and Aldurazyme (laronidase). BioMarin has been transitioning its commercial focus from the mature enzyme replacement franchise toward newer growth drivers (Voxzogo and ROCTAVIAN) with analyst attention on the balance of growth-portfolio contribution versus legacy-franchise stability. Amylyx Pharmaceuticals (NASDAQ: AMLX) also reports Q2 2026 results Thursday August 6 at 8:00 AM ET, with focus on the amyotrophic lateral sclerosis (ALS) pipeline following the March 2024 US withdrawal of Relyvrio and pipeline reprioritization to progressive supranuclear palsy (PSP) and other rare neurodegenerative indications. Tarsus Pharmaceuticals (NASDAQ: TARS) reports at 8:00 AM ET.